UBS Group
LEXX icon

UBS Group’s Lexaria Bioscience LEXX Stock Holding History

UBS Group’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3K Sell
3,131
-383
-11% -$4.15K ﹤0.01% 7981
2026
Q1 		$41.1K Sell
3,514
-20,573
-85% -$224K ﹤0.01% 7498
2025
Q4 		$223K Buy
24,087
+23,614
+4,992% +$335K ﹤0.01% 6521
2025
Q3 		$6.76K Buy
473
+68
+17% +$987 ﹤0.01% 8765
2025
Q2 		$5.28K Buy
+405
New +$6.98K ﹤0.01% 9188
2025
Q1 		– Sell
-8
Closed -$244 – 10505
2024
Q4 		$244 Buy
+8
New +$295 ﹤0.01% 9552
2024
Q1 		– Sell
-302
Closed -$5.67K – 9716
2023
Q4 		$5.67K Buy
+302
New +$5.83K ﹤0.01% 7770
2023
Q3 		– Sell
-7
Closed -$72 – 9741
2023
Q2 		$72 Sell
7
-302
-98% -$5.87K ﹤0.01% 8556
2023
Q1 		$12.6K Sell
309
-64
-17% -$2.73K ﹤0.01% 7433
2022
Q4 		$13.8K Sell
373
-54
-13% -$1.94K ﹤0.01% 8141
2022
Q3 		$16K Buy
427
+149
+54% +$6.37K ﹤0.01% 7691
2022
Q2 		$12K Buy
278
+100
+56% +$4.02K ﹤0.01% 7665
2022
Q1 		$9K Sell
178
-98
-36% -$5.54K ﹤0.01% 8554
2021
Q4 		$17K Buy
+276
New +$23.6K ﹤0.01% 8066

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

UBS Group's LEXX Position: Q2 2026 in Review

UBS Group reduced its Lexaria Bioscience (LEXX) stake by 11% in Q2 2026, selling an estimated $4.15K and leaving 3,131 shares worth $26.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7981.

UBS Group first reported a position in LEXX in Q4 2021 and has held it in 14 quarters since. The position peaked at $223K in Q4 2025. 29 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

  • UBS Group held 3,131 shares of Lexaria Bioscience worth $26.3K as of Q2 2026.
  • UBS Group sold 383 Lexaria Bioscience shares in Q2 2026, an estimated $4.15K.
  • Lexaria Bioscience made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7981 holding.
  • UBS Group first reported a position in Lexaria Bioscience in Q4 2021 and has held it in 14 quarters since.
  • UBS Group's Lexaria Bioscience position peaked at $223K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.